# Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia

> **NCT02611973** · PHASE3 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 2250 (estimated)

## Conditions studied

- MPN
- Essential Thrombocythemia

## Interventions

- **OTHER:** Aspirin therapy interruption
- **OTHER:** Usual treatment by aspirin 100 mg/d in the active comparator arm
- **OTHER:** No interruption of aspirin in the Observational arm
- **DRUG:** Hydroxyurea treatment (HU)

## Key facts

- **NCT ID:** NCT02611973
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03-10
- **Primary completion:** 2019-11
- **Final completion:** 2022-11
- **Target enrollment:** 2250 (ESTIMATED)
- **Last updated:** 2017-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02611973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02611973, "Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02611973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*